Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virus-like particles-universal molecular toolboxes.

Christine Ludwig1, Ralf Wagner

  • 1Molecular Microbiology and Gene Therapy Unit, Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany. christine.ludwig@klinik.uniregensburg.de

Current Opinion in Biotechnology
|December 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNAm landscape up to 4 months post SARS-CoV-2 infection: insights from four population-based cohorts.

Clinical epigenetics·2026
Same author

A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.

The Journal of infection·2026
Same author

Observation versus self-perception: Effectiveness of measures to increase separate bio-waste collection from multi-storey residential buildings.

Waste management & research : the journal of the International Solid Wastes and Public Cleansing Association, ISWA·2026
Same author

Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits.

NPJ vaccines·2025
Same author

Modeling spatiotemporal patterns of microplastic pollution in the lupit river using multilinear regression.

Scientific reports·2025
Same author

Development of a Novel Homogeneous Liposome-Based One-Step Assay for SARS-CoV-2 Antibody Detection in Human Serum Based on Fluorescent Liposomes and Complement Activity.

Analytical chemistry·2025
Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026
Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026
Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026
Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026
Same journal

Harvesting insights from recent advances in yeast genomics for predictable and precision wine fermentation.

Current opinion in biotechnology·2026
Same journal

Minimal enzyme cascades for the aromatic-to-aromatic upgrading of lignin monomers.

Current opinion in biotechnology·2026
See all related articles

Virus-like particles (VLPs) are versatile subviral structures that self-assemble into spheres. These particles show promise for vaccines against infectious diseases and cancer, and in biomaterials development.

Area of Science:

  • Biotechnology
  • Immunology
  • Vaccinology

Background:

  • Virus-like particles (VLPs) are self-assembling, highly organized spheres derived from viral structural antigens.
  • VLPs exhibit potent adjuvant properties, stimulating innate and adaptive immune responses.
  • Successful VLP-based vaccines exist for Hepatitis B Virus (HBV) and Human Papillomavirus (HPV).

Purpose of the Study:

  • To explore the potential of VLPs in combating infectious diseases and cancer.
  • To leverage insights from Human Immunodeficiency Virus (HIV)-derived VLPs for AIDS vaccine development.
  • To investigate VLPs and virosomes as organic templates in nanobiotechnology for novel biomaterials.

Main Methods:

  • Self-assembly of virus-derived structural antigens into VLP structures.

Related Experiment Videos

  • Evaluation of VLP adjuvant properties for immune stimulation.
  • Application of VLP technology in vaccine design and biomaterial development.

    • Main Results:

    • VLPs demonstrate stability and versatility as subviral particles.
    • VLPs have proven efficacy in commercial vaccines and are under investigation for new applications.
    • Human Immunodeficiency Virus (HIV)-VLPs provide valuable insights for vaccine strategies.

    Conclusions:

    • VLPs are promising platforms for developing vaccines against various pathogens and cancers.
    • VLPs and virosomes are emerging as valuable tools in nanobiotechnology for biomaterial innovation.